| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
6'-Galactosyllactose targets the gut microbiota, promoting the growth of beneficial gut bacteria. It reduces inflammation in human T84, NCM-460, and H4 cells and intestinal tissues. It attenuates NF-κB inflammatory signaling in human intestinal epithelial cells. It is a strong anti-inflammatory agent in human colostrum.
|
|---|---|
| ln Vitro |
In vitro, 6'-Galactosyllactose reduces inflammation in human T84, NCM-460, and H4 cells and intestinal tissues. It attenuates NF-κB inflammatory signaling in human intestinal epithelial cells. It is a prebiotic that supports the growth of beneficial gut microbiota.
|
| ln Vivo |
In vivo, 6'-Galactosyllactose is a human milk oligosaccharide with prebiotic effects. It supports the growth of beneficial gut bacteria and modulates carbohydrate metabolism. It reduces inflammation in intestinal tissues. It is an effective antimicrobial and antiviral, and regulator of inflammatory immune cell-response cascades.
|
| Enzyme Assay |
Cell-free assays for 6'-Galactosyllactose: prebiotic activity is assessed by measuring the growth of beneficial gut bacteria (e.g., Bifidobacteria, Lactobacilli) in culture with the compound as the carbon source. Anti-inflammatory activity is assessed by measuring inhibition of NF-κB signaling in cell-free systems.
|
| Cell Assay |
In vitro cellular assays for 6'-Galactosyllactose: human intestinal epithelial cells (e.g., T84, NCM-460, H4) are cultured and treated with 6'-Galactosyllactose at concentrations of 0.1-100 µM for 1-24 hours. NF-κB activation is assessed by reporter gene assays or Western blot. Inflammatory cytokine production is measured by ELISA. Cell viability is assessed by MTT assay.
|
| Animal Protocol |
In vivo animal studies for 6'-Galactosyllactose: animal models of intestinal inflammation (e.g., DSS-induced colitis) or metabolic disorders would be used. Animals are administered 6'-Galactosyllactose orally at doses of 10-50 mg/kg. Gut microbiota composition, inflammatory markers, and intestinal histology are assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of 6'-Galactosyllactose: as an oligosaccharide, it is not absorbed intact. It reaches the colon where it is fermented by gut microbiota. It is metabolized by bacteria to short-chain fatty acids. No systemic pharmacokinetics are applicable.
|
| Toxicity/Toxicokinetics |
Toxicity of 6'-Galactosyllactose: as a human milk oligosaccharide, it is generally considered safe and non-toxic. High doses may cause gastrointestinal effects such as bloating. It is for research use only and not approved for clinical use.
|
| References |
|
| Additional Infomation |
6'-Galactosyllactose is a research compound with potential applications in prebiotic, anti-inflammatory, and gut health research. It is a human milk oligosaccharide with prebiotic and anti-inflammatory properties. No clinical trials or FDA approvals have been reported.
|
| Molecular Formula |
C18H32O16
|
|---|---|
| Molecular Weight |
504.44
|
| Exact Mass |
504.169
|
| CAS # |
32581-31-0
|
| PubChem CID |
101916624
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
-7.2
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
16
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
34
|
| Complexity |
625
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)OC[C@@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)O[C@H]([C@@H](CO)O)[C@@H]([C@H](C=O)O)O)O)O)O)O)O)O)O
|
| InChi Key |
ZCLAHGAZPPEVDX-WGLZGUASSA-N
|
| InChi Code |
InChI=1S/C18H32O16/c19-1-5(22)9(24)16(6(23)2-20)34-18-15(30)13(28)11(26)8(33-18)4-31-17-14(29)12(27)10(25)7(3-21)32-17/h1,5-18,20-30H,2-4H2/t5-,6+,7+,8+,9+,10-,11-,12-,13-,14+,15+,16+,17+,18-/m0/s1
|
| Chemical Name |
(2R,3R,4R,5R)-2,3,5,6-tetrahydroxy-4-[(2S,3R,4S,5R,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9824 mL | 9.9120 mL | 19.8240 mL | |
| 5 mM | 0.3965 mL | 1.9824 mL | 3.9648 mL | |
| 10 mM | 0.1982 mL | 0.9912 mL | 1.9824 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA